Director - Real World Data (RWD) Strategy - Immunology

At Lilly, the work is demanding because patients are waiting. We unite caring with discovery to help make life better for people around the world, knowing that every decision, every detail, and every day matters. Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life-changing medicines, strengthen how health is understood and managed, and support the communities we serve. This is hard, urgent, selfless work—but it’s work worth doing. If you’re driven by purpose and ready to bring your best to work that truly matters for patients, we invite you to join us. 

The Director, RWD Strategy serves as Lilly's enterprise champion for RWD in Immunology, translating the rapidly evolving external data landscape into a coherent, high-impact internal strategy that accelerates drug development, strengthens regulatory submissions, and maximizes the scientific and commercial return on Lilly's RWD investments. This role operates at the intersection of science, strategy, execution, and innovation — owning the enterprise vision for how RWD in Immunology is identified, evaluated, acquired, governed, and leveraged across the full product lifecycle, from early development through post-marketing, and across therapeutic areas and business units. The leader in this role is proficient in scientific methodology and business strategy, capable of engaging credibly with scientists and senior leadership on portfolio prioritization and operational execution, and with data architects and engineers on infrastructure requirements.

Beyond portfolio-level governance and data stewardship, this leader is expected to actively shape the future of RWD at Lilly — by integrating AI and emerging technologies into the RWD workflow, building federated and privacy-preserving data capabilities, connecting RWD insights to clinical trial design and regulatory strategy, and ensuring Lilly's data assets reflect the diversity and complexity of real-world patient populations. The role carries responsibility not just for executing today's RWD agenda, but for anticipating what the field will require in three to five years and positioning Lilly to lead it.

This is a critical role requiring strong cross-functional influence, scientific credibility, external thought leadership, and the strategic judgment to align Lilly's RWD investments with its most important business and patient impact priorities.

Leadership in Real World Data Strategy

• Develop and drive the strategic vision for Immunology RWD utilization across the product lifecycle, from early development through post-marketing and connecting opportunities across functions for maximizing RWD use for patient and Lilly impact and in close collaboration with enterprise-level RWD acquisitions.
• Create a systematic framework for quantifying the value delivered by RWD investments — in terms of regulatory impact, commercial value, publications, clinical development acceleration, or avoided costs.
• Define and track enterprise RWD performance KPIs to measure impact, improve decision‑making, and optimize RWD investments
• Own Immunology RWD data landscaping and inventory across HEOR, SDIA, Statistics, Medical, Clinical, Regulatory and other functions
• Maintain a deep understanding of external landscape for RWD, knowledge of Lilly licensed RWD, and manage the inventory of RWD.
• Maintain ongoing competitive intelligence on external RWD strategy, data source adoption, regulatory submissions supported by RWE, and emerging data modalities, and translating these insights into strategic recommendations for Lilly's Immunology and enterprise RWD portfolio.
• Collaborate cross-functionally with key Lilly stakeholders (e.g. Medical Affairs, SDIA, BI&A, HEOR, Epidemiology, Lilly Value Access, Tech@Lilly,  etc) to identify data gaps, redundancies and opportunities where RWD can inform decision making to avoid redundancy and improve ROI.
• Lead the identification, evaluation, acquisition and cross-BU coordination of fit-for-purpose, high-value Immunology RWD sources (e.g., Pharmetrics, Truveta), aligned with scientific and business needs that match RWD sources to research questions
• Establish and operationalize systematic data landscaping as the enterprise process for identifying, evaluating, and prioritizing RWD sources
• Evaluate and operationalize federated learning partnerships, synthetic data use cases, and privacy-enhancing computation methods, in collaboration with Tech@Lilly and external data partners.
• Lead the development, communication, and adherence to RWD health information standards, tools and technology and processes for RWE generation, with a particular focus on leveraging RWD/E in regulatory decision.
• Develop strategy for integrating SDOH, patient-reported outcomes, digital/wearable bio